Is the Expression of the Components of the Carotid Matrix of Rats Influenced by Estrogen, Progestin and Tibolone?

Abstract

Objective To analyze the effects of estrogen alone or in combination with progestogens and tibolone (TIB) on the expression of the extracellular matrix metalloproteinases 2 and 9 (MMP-2 and MMP-9), of perlecan, and of heparanase (HPSE) of the vascular walls of the carotid arteries.

Methods A total of 30 250-day-old ovariectomized Wistar rats were orally treated for 5 weeks with: a) 1 mg/kg of estradiol benzoate (EB); b) EB + 0.2 mg/kg of medroxyprogesterone acetate (MPA); c) EB + 0.2mg/kg of norethisterone acetate (NETA); d) EB + 2 mg/kg of dydrogesterone (DI); e) 1 mg/kg of TIB; f) placebo (CTR). Following treatment, the expression of mRNA for MMP-2, MMP-9, and HPSE was analyzed by real-time polymerase chain-reaction (PCR), and the expression of MMP-2, of MMP-9, of tissue inhibitor of metalloproteinase 2 (TIMP-2), and of perlecan was quantified by immunohistochemistry in the carotid arteries.

Results The groups showed significant differences on mRNA HPSE expression (p = 0.048), which was higher in the EB, EB + MPA, and TIB groups. There was no statistically significant difference in mRNA MMP-2 or MMP-9 expression. The immunohistochemical expression of MMP-2, of TIMP-2, of MMP-9, of HPSE, and of perlecan showed no differences between groups.

Conclusion Estradiol alone or associated with MPA and TIB treatment can increase mRNA HSPE expression of the walls of the carotid arteries in ovariectomized rats.

Resumo

Objetivo Analisar os efeitos do estrogênio isolado ou em combinação com progestogênios e tibolona (TIB) na expressão das metaloproteinases 2 e 9 da matriz extracelular (MMP-2 e MMP-9), da perlecan e da heparanase (HPSE) das paredes vasculares das artérias carótidas.

Métodos Trinta ratas Wistar ovariectomizadas com 250 dias de idade foram tratadas oralmente por 5 semanas com: a) 1 mg/kg de benzoato de estradiol (EB); b) EB + 0,2 mg/kg de acetato de medroxiprogesterona (MPA); c) EB + 0,2mg/kg de acetato de noretisterona (NETA); d) EB + 2 mg/kg de didrogesterona (DI); e) 1 mg/kg de TIB; f) placebo (CTR). Após o tratamento, a expressão de mRNA para MMP-2, MMP-9, e HPSE foi analisada por reação em cadeia da polimerase (RCP) em tempo real, e a expressão de MMP-2, MMP-9, inibidor tecidual de metaloproteinase 2 (TIMP-2), e de perlecan foi quantificado por imunohistoquímica em artérias carótidas.

Resultados Os grupos apresentaram diferenças significativas na expressão do mRNA HPSE (p = 0,048), sendo maiores nos grupos EB, EB + MPA e TIB. Não houve diferença estatisticamente significativa nas expressões de mRNA MMP-2 ou MMP-9. A expressão imunohistoquímica de MMP-2, TIMP-2, MMP-9, HPSE e perlecan não mostrou diferenças entre os grupos.

Conclusão O estradiol isolado ou associado ao tratamento com MPA e TIB pode aumentar a expressão de mRNA HSPE nas paredes das artérias carótidas em ratas ovariectomizadas.

Keywords

extracellular matrix - proteoglycans - atherosclerosis - estrogen - progestogen - tibolone

Palavras-chave

matriz extracelular - proteoglicanos - aterosclerose - estrogênio - progestogênio - tibolona

Contributors

Steiner M. L., Theodoro T. R., Garcia S. G., Mader A. M. A. A., Pompei L. M., Pinhal M. A. S., and Fernandes C. E. contributed with the project and the interpretation of data, the writing of the article, the critical review of the intellectual content, and with the final approval of the version to be published.

• References

• 1 Toole JF, Chambless LE, Heiss G, Tyroler HA, Paton CC. Prevalence of stroke and transient ischemic attacks in the Atherosclerosis Risk in Communities (ARIC) study. Ann Epidemiol 1993; 3 (05) 500-503 . Doi: 10.1016/1047-2797(93)90104-C
• 2 Kannel WB, Hjortland MC, McNamara PM, Gordon T. Menopause and risk of cardiovascular disease: the Framingham study. Ann Intern Med 1976; 85 (04) 447-452 . Doi: 10.7326/0003-4819-85-4-447
• 3 Clarkson TB, Meléndez GC, Appt SE. Timing hypothesis for postmenopausal hormone therapy: its origin, current status, and future. Menopause 2013; 20 (03) 342-353 . Doi: 10.1097/GME.0b013e3182843aad
• 4 Lopes N, Vasudevan SS, Alvarez RJ, Binkley PF, Goldschmidt PJ. Pathophysiology of plaque instability: insights at the genomic level. Prog Cardiovasc Dis 2002; 44 (05) 323-338
• 5 Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002; 90 (03) 251-262 . Doi: 10.1161/res.90.3.251
• 6 Heo SH, Cho CH, Kim HO. , et al. Plaque rupture is a determinant of vascular events in carotid artery atherosclerotic disease: involvement of matrix metalloproteinases 2 and 9. J Clin Neurol 2011; 7 (02) 69-76 . Doi: 10.3988/jcn.2011.7.2.69
• 7 Kruegel J, Miosge N. Basement membrane components are key players in specialized extracellular matrices. Cell Mol Life Sci 2010; 67 (17) 2879-2895 . Doi: 10.1007/s00018-010-0367-x
• 8 Farach-Carson MC, Carson DD. Perlecan--a multifunctional extracellular proteoglycan scaffold. Glycobiology 2007; 17 (09) 897-905 . Doi: 10.1093/glycob/cwm043
• 9 Tannock LR, King VL. Proteoglycan mediated lipoprotein retention: a mechanism of diabetic atherosclerosis. Rev Endocr Metab Disord 2008; 9 (04) 289-300 . Doi: 10.1007/s11154-008-9078-0
• 10 Matan M, Axelman E, Brenner B, Nadir Y. Heparanase procoagulant activity is elevated in women using oral contraceptives. Hum Reprod 2013; 28 (09) 2372-2380 . Doi: 10.1093/humrep/det257
• 11 Pompei LM, Steiner ML, Theodoro TR. , et al. Effect of estrogen therapy on vascular perlecan and metalloproteinases 2 and 9 in castrated rats. Climacteric 2013; 16 (01) 147-153 . Doi: 10.3109/13697137.2012.667173
• 12 Fernandes CE, Pompei LM, Machado RB, Ferreira JA, Melo NR, Peixoto S. Effects of estradiol and norethisterone on lipids, insulin resistance and carotid flow. Maturitas 2008; 59 (03) 249-258 . Doi: 10.1016/j.maturitas.2008.02.001
• 13 Christodoulakos GE, Panoulis CP, Lambrinoudaki IV. , et al. The effect of hormone therapy and raloxifene on serum matrix metalloproteinase-2 and -9 in postmenopausal women. Menopause 2004; 11 (03) 299-305 . Doi: 10.1097/01.GME.0000097848.95550.07
• 14 Wakatsuki A, Ikenoue N, Shinohara K, Watanabe K, Fukaya T. Different effects of oral and transdermal estrogen replacement therapy on matrix metalloproteinase and their inhibitor in postmenopausal women. Arterioscler Thromb Vasc Biol 2003; 23 (10) 1948-1949 . Doi: 10.1161/01.ATV.0000090569.11739.B9
• 15 Zanger D, Yang BK, Ardans J. , et al. Divergent effects of hormone therapy on serum markers of inflammation in postmenopausal women with coronary artery disease on appropriate medical management. J Am Coll Cardiol 2000; 36 (06) 1797-1802 . Doi: 10.1016/S0735-1097(00)00952-9
• 16 Marfella R, Di Filippo C, Portoghese M. , et al. Proteasome activity as a target of hormone replacement therapy-dependent plaque stabilization in postmenopausal women. Hypertension 2008; 51 (04) 1135-1141 . Doi: 10.1161/HYPERTENSIONAHA.107.105239
• 17 Sophonsritsuk A, Appt SE, Clarkson TB, Shively CA, Espeland MA, Register TC. Differential effects of estradiol on carotid artery inflammation when administered early versus late after surgical menopause. Menopause 2013; 20 (05) 540-547 . Doi: 10.1097/GME.0b013e31827461e0
• 18 Lekontseva O, Jiang Y, Davidge ST. Estrogen replacement increases matrix metalloproteinase contribution to vasoconstriction in a rat model of menopause. J Hypertens 2009; 27 (08) 1602-1608 . Doi: 10.1097/HJH.0b013e32832c41b5
• 19 Hwang-Levine J, Stanczyk FZ, Hodis HN. The role of progestogens in regulating matrix metalloproteinase activity in macrophages and microglial cells. Neurochem Res 2011; 36 (10) 1870-1875 . Doi: 10.1007/s11064-011-0508-0